Synergy Spine Solutions Reports Two-Year Synergy Disc Outcomes
Miami, Florida, USA, September 16, 2026 Synergy Spine Solutions® has highlighted new two-year clinical outcomes for its FDA-approved Synergy...
AI drug discovery artificial intelligence Autoimmune Disease biologics Biomarkers biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cancer Treatment Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery FDA fda approval FDA clearance Gene Therapy healthcare technology immunology Immunotherapy Medical Device Medical Devices MedTech Monoclonal Antibody Neurology Oncology Ophthalmology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
Miami, Florida, USA, September 16, 2026 Synergy Spine Solutions® has highlighted new two-year clinical outcomes for its FDA-approved Synergy...
NEW YORK and TORONTO, July 21, 2026 Helus Pharma has announced the successful completion of patient enrollment ahead of...
LOUISVILLE, Colo., July 21, 2026 Synergy Spine Solutions has announced a major commercial milestone for its FDA-approved Synergy Disc®,...
